The history and future of targeting cyclin-dependent kinases in cancer therapy
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Cited by
Items 101–200 of 1,002
Guarducci, C., Bonechi, M., Benelli, M., Biagioni, C., Boccalini, G., Romagnoli, D., Verardo, R., Schiff, R., Osborne, C. K., Angelis, C. D., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0092-4 · Cited by 153
INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Dietrich, C. A., Trub, A. G., Ahn, A., Taylor, M., Ambani, K., Chan, K. T., Lu, K., Mahendra, C. A., Blyth, C., Coulson, R. S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0954 · Cited by 154
“However, many early attempts to develop inhibitors of CDK were unsuccessful due to poor compound selectivity resulting in unfavorable toxicity profiles (2).”
Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer
Heffron, T. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00618 · Cited by 151
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
Winer, E. S., & Stone, R. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719860645 · Cited by 148
Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma
Yang, Z., Li, X., Yang, Y., He, Z., Qu, X., & Zhang, Y. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.272 · Cited by 144
“Both oncogene activation and tumor suppressor gene inactivation lead to cancer occurrence and development.(106,107) In osteosarcoma, lncRNAs also exhibit oncogenic properties or act as tumor suppressors to control osteosarcoma progression by regulating cell cycle progression or cell apoptosis to regulate cell prolifer…”
BackgroundGórski, J., Ueland, F. R., & Kolesar, J. (2020) · Diagnostics · doi:10.3390/diagnostics10050279 · Cited by 144
“Some trials have been withdrawn due to the associated side effects of off-target kinase inhibition and failure to reach an appropriate clinical outcome [60].”
BackgroundTargeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers
Santo, L., Siu, K. T., & Raje, N. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.024 · Cited by 142
Oshi, M., Takahashi, H., Tokumaru, Y., Yan, L., Rashid, O. M., Nagahashi, M., Matsuyama, R., Endo, I., & Takabe, K. (2020) · Cells · doi:10.3390/cells9071643 · Cited by 143
A Dynamical Framework for the All-or-None G1/S Transition
Barr, A. R., Heldt, F. S., Zhang, T., Bakal, C., & Novák, B. (2016) · Cell Systems · doi:10.1016/j.cels.2016.01.001 · Cited by 125
“Moreover, many cancer cells do not have an intact restriction point (Asghar et al., 2015), and thus, inhibition of the G1/S transition is an attractive therapeutic target to stop these cancer cells from proliferating.”
Backgroundp16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells
Majewska, J., Agrawal, A., Mayo, A., Roitman, L., Chatterjee, R., Sekeresova Kralova, J., Landsberger, T., Katzenelenbogen, Y., Meir-Salame, T., Hagai, E., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01465-0 · Cited by 114
“To test if PD-L1 upregulation is enhanced by p16-mediated inhibition of CDKs, we treated growing primary fibroblasts with highly selective inhibitors of CDK4 and CDK6 (CDK4/6i), abemaciclib or palbociclib, which can be considered functional p16 mimetics 19 .”
Revealing quinquennial anticancer journey of morpholine: A SAR based review
Arshad, F., Khan, M. F., Akhtar, W., Alam, M. M., Nainwal, L. M., Kaushik, S. K., Akhter, M., Parvez, S., Hasan, S. M., & Shaquiquzzaman, M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.015 · Cited by 139
Curcumol: From Plant Roots to Cancer Roots
Wei, W., Rasul, A., Sadiqa, A., Sarfraz, I., Hussain, G., Nageen, B., Liu, X., Watanabe, N., Selamoğlu, Z., Ali, M., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.34716 · Cited by 139
“Since cancer represents a pathological condition with uncontrolled cellular division [58], therefore, naturally occurring bioactive entities regulating cell cycle or inhibiting mitotic divisions are affirmed to be promising candidates for chemotherapies [59, 60].”
BackgroundKnudsen, E. S., Kumarasamy, V. M., Nambiar, R., Pearson, J. D., Vail, P. J., Rosenheck, H. R., Wang, J., Eng, K., Bremner, R., Schramek, D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110448 · Cited by 141
“Targeting the cell cycle as a means to treat cancer is appealing since deregulated proliferation is achieved mechanistically through mitotic cell division (Asghar et al., 2015; Shapiro, 2006; Suski et al., 2021).”
BackgroundSelf-citationCoxon, C. R., Anscombe, E., Harnor, S. J., Martin, M. P., Carbain, B., Golding, B. T., Hardcastle, I. R., Harlow, L. K., Korolchuk, S., Matheson, C. J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01254 · Cited by 137
Albanese, A., Daly, L. A., Mennerich, D., Kietzmann, T., & Sée, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010268 · Cited by 136
“Cyclindependent kinases (CDKs) belong to an important family of proteins involved in regulating and fine -tuning several stages of the cell cycle [56].”
BackgroundSelective degradation of CDK6 by a palbociclib based PROTAC
Rana, S., Bendjennat, M., Kour, S., King, H. M., Kizhake, S., Zahid, M., & Natarajan, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.035 · Cited by 135
Bisi, J., Sorrentino, J. A., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0775 · Cited by 135
1,2,4-Triazolo[1,5-a]pyrimidines in drug design
Oukoloff, K., Lucero, B., Francisco, K. R., Brunden, K. R., & Ballatore, C. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.027 · Cited by 135
Pan-cancer molecular analysis of the RB tumor suppressor pathway
Knudsen, E. S., Nambiar, R., Rosario, S. R., Smiraglia, D. J., Goodrich, D. W., & Witkiewicz, A. K. (2020) · Communications Biology · doi:10.1038/s42003-020-0873-9 · Cited by 138
Self-citationOvercoming Cancer Drug Resistance Utilizing PROTAC Technology
Burke, M. R., Smith, A. R., & Zheng, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.872729 · Cited by 134
Rahim, B. G., & O'Regan, R. M. (2017) · Cancers · doi:10.3390/cancers9030021 · Cited by 132
“These kinases are activated by cyclin D, and promote cell cycle entry by phosphorylating proteins that drive the transition from G1 to the S1 phase and when disrupted can lead to unrestricted cell proliferation in breast cancer [129,130].”
BackgroundWang, Y., Zhi, Y., Jin, Q., Lü, S., Lin, G., Yuan, H., Yang, T., Wang, Z., Yao, C., Ling, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01261 · Cited by 132
Cell Cycle–Targeted Cancer Therapies
Sherr, C. J., & Bártek, J. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-040716-075628 · Cited by 130
“…cancer cells versus normal cells, and were unacceptably toxic in the clinic (Asghar et al. 2015, Diaz-Moralli et al. 2013), potent and specific orally available chemical inhibitors of CDK4 and CDK6 have recently emerged as targeted therapeutics for cancer (Asghar et al. 2015, Sherr et al. 2016).”
BackgroundDickler, M. N., Barry, W. T., Cirrincione, C., Ellis, M. J., Moynahan, M. E., Innocenti, F., Hurria, A., Rugo, H. S., Lake, D. E., Hahn, O. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1595 · Cited by 128
Diab, A., Foca, A., Zoulim, F., Durantel, D., & ANDRISANI, O. M. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.11.015 · Cited by 129
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Table 1 Kinases that phosphorylate HBc. Kinase Effect on viral replication Immuno-detected in capsids Phosphorylation sites References PKC Required for envelop…”
BackgroundInfluentialXue, Y., Meehan, B., Macdonald, E. A., Venneti, S., Wang, X. Q. D., Witkowski, L., Jelinic, P., Kong, T., Martínez, D., Morin, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-06958-9 · Cited by 128
A Comprehensive Review on Schisandrin B and Its Biological Properties
Nasser, M. I., Zhu, S., Chen, C., Zhao, M., Huang, H., & Zhu, P. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2172740 · Cited by 128
“Under the specific circumstance, they can go into the cell cycle and start splitting again (Figure 1) [34, 35].”
BackgroundOnesti, C. E., & Jérusalem, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1852934 · Cited by 128
Cellular Senescence and Ageing: Mechanisms and Interventions
Mylonas, A., & O’Loghlen, A. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.866718 · Cited by 106
“CDK inhibitors, in particular CDK4/6 inhibitors (Abemaciclib, Palbociclib and Ribociclib), induce cell-cycle arrest and subsequent senescence in several cancer cell lines and mouse models (Asghar et al., 2015; Alvarez-Fernandez and Malumbres, 2020; Carpintero-Fernandez et al., 2022).”
BackgroundGoto, Y., Kurozumi, A., Arai, T., Nohata, N., Kojima, S., Okato, A., Kato, M., Yamazaki, K., Ishida, Y., Naya, Y., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.191 · Cited by 126
“CDK1 is a key regulator of the cell cycle and forms a complex with cyclin A and cyclin B in G1/S- and G2/M-phase transitions (Asghar et al, 2015).”
BackgroundMolecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma
Cardoso, L., Stevenson, M., & Thakker, R. V. (2017) · Human Mutation · doi:10.1002/humu.23337 · Cited by 126
Presti, D., & Quaquarini, E. (2019) · Cancers · doi:10.3390/cancers11091242 · Cited by 129
“During the DNA synthesis phase of the cell cycle, the cyclin D-CDK4/6 complex serves as the enzyme that catalyzes the phosphorylation of the retinoblastoma (RB) protein and dictates DNA replication [5,6,11,14].”
BackgroundInfluentialHighlights in Resistance Mechanism Pathways for Combination Therapy
Delou, J. M. D. A., Souza, A. S. O., Souza, L. C. D. M. E., & Borges, H. L. (2019) · Cells · doi:10.3390/cells8091013 · Cited by 128
“Flavopiridol was tested in more than 60 clinical trials for 15 years, mostly with disappointing degrees of antitumor activity [76,78].”
Quantifying CDK inhibitor selectivity in live cells
Wells, C. I., Vasta, J. D., Corona, C. R., Wilkinson, J., Zimprich, C. A., Ingold, M. R., Pickett, J. E., Drewry, D. H., Pugh, K. M., Schwinn, M. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16559-0 · Cited by 114
Wang, K., Russell, J. S., McDermott, J. D., Elvin, J. A., Khaira, D., Johnson, A., Jennings, T. A., Ali, S. M., Murray, M., Marshall, C. B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2568 · Cited by 124
“Because of diversity and complexity of CDK signaling, it has been difficult to develop CDK-targeted therapies (37).”
BackgroundO’Shaughnessy, J., Petráková, K., Sonke, G. S., Conte, P., Arteaga, C. L., Cameron, D., Hart, L. L., Villanueva, C., Jakobsen, E. H., Beck, J. T., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4518-8 · Cited by 127
“The hematologic toxicities of neutropenia, leukopenia, and anemia were among the most frequent adverse events in the ribociclib plus letrozole arm, consistent with the known on-target effect of CDK4/6 inhibitors on hematologic precursors in the bone marrow [25].”
BackgroundLiao, P., Zeng, S. X., Zhou, X., Chen, T., Zhou, F., Cao, B., Jung, J. H., Del Sal, G., Luo, S., & Lu, H. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.11.006 · Cited by 113
“Many tumorigenic events, including liver carcinogenesis, ultimately drive proliferation by impinging on CDK4 complexes in the G1 phase of the cell cycle (Asghar et al., 2015).”
BackgroundPoratti, M., & Marzaro, G. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.064 · Cited by 123
Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery
Mateus, A., Gordon, L. J., Wayne, G. J., Almqvist, H., Axelsson, H., Seashore-Ludlow, B., Treyer, A., Matsson, P., Lundbäck, T., West, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701848114 · Cited by 103
Development of selective mono or dual PROTAC degrader probe of CDK isoforms
Zhou, F., Chen, L., Cao, C., Yu, J., Luo, X., Zhou, P., Zhao, L., Du, W., Cheng, J., Xie, Y., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111952 · Cited by 110
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update
Wu, T., Qin, Z., Tian, Y., Wang, J., Xu, C., Li, Z., & Bian, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00744 · Cited by 121
CDK inhibitors from past to present: A new wave of cancer therapy
Jameel, M., Bhadresha, K. P., & Kwok, H. F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.006 · Cited by 121
Regulation and targeting of SREBP-1 in hepatocellular carcinoma
Su, F., & Koeberle, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10156-5 · Cited by 122
“…by GSK3, AMPK, and PKA [134, 214, 284], as discussed in the “Protein kinases” section, “AMPK” section, and “PKA” section. mSREBP-1 is also directly phosphorylated at S439 and thereby stabilized by the cyclin-dependent kinase 1 (Cdk1)/cyclin B complex [312], which coordinates G2/M progression [313].”
BackgroundClinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
Barroso-Sousa, R., Shapiro, G. I., & Tolaney, S. M. (2016) · Breast Care · doi:10.1159/000447284 · Cited by 110
Potential Anticancer Properties and Mechanisms of Action of Formononetin
Jiang, D., Rasul, A., Batool, R., Sarfraz, I., Hussain, G., Tahir, M. M., Tian, Q., Selamoğlu, Z., Ali, M., Li, J., et al. (2019) · BioMed Research International · doi:10.1155/2019/5854315 · Cited by 119
“Uncontrolled divisions of cells are key trait of cancer cells [69].”
BackgroundAsghar, U. S., Kanani, R., Roylance, R. R., & Mittnacht, S. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00002 · Cited by 120
Self-citationCardamonin: A new player to fight cancer via multiple cancer signaling pathways
Nawaz, J., Rasul, A., Shah, M. A., Hussain, G., Riaz, A., Sarfraz, I., Zafar, S., Adnan, M., Khan, A. H., & Selamoğlu, Z. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117591 · Cited by 119
Subhan, M. A., Parveen, F., Shah, H., Yalamarty, S. S. K., Ataide, J. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15082204 · Cited by 118
“Deregulated cyclin D1 is frequent in breast cancer [158].”
BackgroundGenetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Knudsen, E. S., O’Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 107
Self-citationCombined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms
Olmez, I., Brenneman, B. R., Xiao, A., Serbulea, V., Benamar, M., Zhang, Y., Manigat, L. C., Abbas, T., Lee, J., Nakano, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0803 · Cited by 119
“Single-agent palbociclib has failed to provide durable therapeutic response in various clinical trials (8, 30), prompting a search for combinatorial approaches.”
BackgroundSabbaghi, M., Gil-Gómez, G., Guardia, C., Servitja, S., Arpí, O., García-Alonso, S., Menendez, S., Arumi-Uria, M., Serrano, L., Salido, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0696 · Cited by 102
“On the other hand, our results showing that CDK1/Cyclin B1 activity is needed for T-DM1 action suggests a note of caution regarding possible combinations of T-DM1 with pan-CDKs inhibitors or selective CDK1 inhibitors (30).”
ResultCDK4/6 regulate lysosome biogenesis through TFEB/TFE3
Yin, Q., Jian, Y., Xu, M., Huang, X., Wang, N., Liu, Z., Li, Q., Li, J., Zhou, H., Xu, L., et al. (2020) · Journal of Cell Biology · doi:10.1083/jcb.201911036 · Cited by 108
Li, B., Jin, J., Guo, D., Tao, Z., & Hu, X. (2023) · Cancers · doi:10.3390/cancers15102858 · Cited by 117
“Highly selective CDK4/6 inhibitors had significant efficacy and tolerant toxicity in hormone receptor positive breast cancer and were in an exploratory status in other tumors [105,106].”
BackgroundA unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib
Chong, Q.-Y., Kok, Z. H., Bui, N.-L.-C., Xiang, X., Wong, A. L., Yong, W. P., Sethi, G., Lobie, P. E., Wang, L., & Goh, B.-C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104686 · Cited by 115
Eldehna, W. M., Hassab, M. A. E., Abo-Ashour, M. F., Al-Warhi, T. I., Elaasser, M. M., Safwat, N. A., Suliman, H. S., Ahmed, M. F. E., Al‐Rashood, S. T., Abdel‐Aziz, H. A., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104748 · Cited by 115
Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth
Guan, X., LaPak, K. M., Hennessey, R. C., Yu, C. Y., Shakya, R., Zhang, J., & Burd, C. E. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0319 · Cited by 106
Tetrandrine and cancer – An overview on the molecular approach
Bhagya, N., & Chandrashekar, K. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.116 · Cited by 114
Differential impact of RB status on E2F1 reprogramming in human cancer
McNair, C. M., Xu, K., Mandigo, A. C., Benelli, M., Leiby, B. E., Rodrigues, D. N., Lindberg, J., Grönberg, H., Crespo, M., Laere, B. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93566 · Cited by 114
Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
Górecki, L., Andrš, M., & Korábečný, J. (2021) · Cancers · doi:10.3390/cancers13040795 · Cited by 113
“For more details about the development and progress of CDK inhibitors, readers are kindly referred to other reviews [2,11,86,87].”
BackgroundChohan, T. A., Qayyum, A., Rehman, K., Tariq, M., & Akash, M. S. H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.116 · Cited by 112
The Centrosome and the Primary Cilium: The Yin and Yang of a Hybrid Organelle
Joukov, V., & Nicolo, A. D. (2019) · Cells · doi:10.3390/cells8070701 · Cited by 112
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
Bonelli, M. A., Monica, S. L., Fumarola, C., & Alfieri, R. R. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113676 · Cited by 112
Pharmacological properties of indirubin and its derivatives
Lin, Y., Li, X., Huang, W., Rao, X., & Lai, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113112 · Cited by 112
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1510345 · Cited by 100
Self-citationSuper-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma
Jiang, Y. Y., Jiang, Y.-Y., Mayakonda, A., Huang, M., Ding, L., Han, L., Yu, F., Lu, Y., Loh, T. K. S., Chow, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1143 · Cited by 112
“regulators (26, 27), we further investigated them using 14 different CDK-inhibitors in 7 NPC cell lines.”
Therapeutic targeting of transcriptional cyclin-dependent kinases
Galbraith, M. D., Bender, H., & Espinosa, J. M. (2018) · Transcription · doi:10.1080/21541264.2018.1539615 · Cited by 111
“In the last ~ 20 years numerous small molecule CDK inhibitors have been developed as potential therapeutics and tested inmultiple cancer types and clinical trials [26].”
BackgroundInfluentialWei, M., Zhao, R., Cao, Y., Wei, Y., Li, M., Dong, Z., Liu, Y., Ruan, H., Li, Y., Cao, S., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112903 · Cited by 107
Niu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 110
“CDK4/6 inhibitors bind to the ATP-binding pocket existed in protein kinases, and thereby block downstream CDK4/6-mediated phosphorylation of Rb [17].”
BackgroundInfluentialIntegrating the DNA damage and protein stress responses during cancer development and treatment
Gorgoulis, V. G., Pefani, D., Pateras, I. S., & Trougakos, I. P. (2018) · The Journal of Pathology · doi:10.1002/path.5097 · Cited by 108
“In addition to inhibitors of replication stress, cell-cycle checkpoint inhibitors against the Wee1 kinase and several CDKs, are also in development as stand-alone or combination therapies [383,384].”
BackgroundCyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
Ma, H., Seebacher, N. A., Hornicek, F. J., & Duan, Z. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.022 · Cited by 108
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
Yi, J., Liu, C., Tao, Z., Wang, M., Jia, Y., Sang, X., Shen, L., Xue, Y., Jiang, K., Luo, F., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.027 · Cited by 108
“Blocking CDK4/6 will lead to the suppression of retinoblastoma protein (RB) phosphorylation and concomitant inhibition of G1-S cell-cycle progression through repressing E2F-mediated transcription [18].”
BackgroundResultInfluentialWang, J., Li, X.-M., Bai, Z., Chi, B., Yan, W., & Chen, X. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.06.037 · Cited by 108
Medicinal attributes of pyridine scaffold as anticancer targeting agents
Mohamed, E. A., Ismail, N. S. M., Hagras, M., & Refaat, H. M. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00165-4 · Cited by 107
“By attacking both androgen receptor activity and anti-apoptotic proteins, CDK9 inhibitors can supply a novel and greater therapeutic scope over conventional treatment choice [28, 29].”
BackgroundCell cycle dysregulation in cancer
Glaviano, A., Singh, S. K., Lee, E. H. C., Okina, E., Lam, H. Y., Carbone, D., Reddy, E. P., O’Connor, M. J., Koff, A., Singh, G., et al. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100030 · Cited by 110
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer
Witkiewicz, A. K., Chung, S., Brough, R., Vail, P. J., Franco, J., Lord, C. J., & Knudsen, E. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.022 · Cited by 106
“Prior studies have suggested that RB can play multiple distinct roles in the context of therapeutic interventions (Asghar et al., 2015; Knudsen and Knudsen, 2008; Knudsen and Wang, 2010).”
BackgroundSelf-citationGordon, E. M., Ravicz, J. R., Liu, S., Chawla, S. P., & Hall, F. L. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1657 · Cited by 106
“Despite the disappointing early attempts to develop pharmaceutical CDKIs for cancer therapy, a more specific focus on the cellular activities of CDK4 and CDK6, which are activated by the oncogenic D‑type cyclins, has recently achieved limited success (47,48).”
Koppenhafer, S. L., Goss, K. L., Terry, W. W., & Gordon, D. J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0585 · Cited by 106
“The classical view is that CDK2 regulates entry into S phase and the initiation of DNA replication, while entry into M phase requires the activity of CDK1 (27,46).”
BackgroundLiu, H., Qiu, W., Sun, T., Wang, L., Du, C., Hu, Y., Liu, W., Feng, F., Yao, C., & Sun, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.019 · Cited by 107
Misactivation of Hedgehog signaling causes inherited and sporadic cancers
Raleigh, D. R., & Reiter, J. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120850 · Cited by 106
“Potent small-molecule inhibitors of CDK6 and the related kinase CDK4 have been tested in diverse human malignancies, and are now being investigated in pediatric medulloblastoma patients (92).”
BackgroundAurone: A biologically attractive scaffold as anticancer agent
Alsayari, A., Muhsinah, A. B., Hassan, M. Z., Ahsan, M. J., Alshehri, J. A., & Begum, N. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.078 · Cited by 105
Genomic insights into head and neck cancer
Beck, T. N., & Golemis, E. A. (2016) · Cancers of the Head & Neck · doi:10.1186/s41199-016-0003-z · Cited by 104
“A large number of CDK inhibitors are currently in development [162] and the possibility of RB1 phosphorylation status as a response predictive biomarker is encouraging [56].”
MYCN induces neuroblastoma in primary neural crest cells
Olsen, R. R., Otero, J. H., García-López, J., Wallace, K., Finkelstein, D., Rehg, J. E., Yin, Z., Wang, Y.-D., & Freeman, K. W. (2017) · Oncogene · doi:10.1038/onc.2017.128 · Cited by 102
Spring, L. M., Bardia, A., & Modi, S. (2016) · PubMed · Cited by 105
Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer
Francavilla, C., Lupia, M., Tsafou, K., Villa, A., Kowalczyk, K. M., Jersie-Christensen, R., Bertalot, G., Confalonieri, S., Brunak, S., Jensen, L. J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.015 · Cited by 102
“, 2014), can be combined with the blockade of transcriptional regulators (Asghar et al., 2015; Gonda and Ramsay, 2015).”
BackgroundCell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers
Hydbring, P., Wang, Y., Fassl, A., Li, X., Matía, V., Otto, T., Choi, Y. J., Sweeney, K. E., Suski, J. M., Yin, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.004 · Cited by 101
“…A uthor M anuscript A uthor M anuscript A uthor M anuscript abemaciclib and ribociclib) received a “Breakthrough Therapy” designation from the Food and Drug Administration and were approved for treatment of estrogen receptor-positive breast cancers (Asghar et al., 2015; Finn et al., 2015).”
InfluentialThe Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma
García-Reyes, B., Kretz, A.-L., Ruff, J.-P., von Karstedt, S., Hillenbrand, A., Knippschild, U., Henne‐Bruns, D., & Lemke, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103219 · Cited by 102
“Flavopiridol 1, 2, 4, 6, 7, 9 [26] Phase I Chronic Lymphocytic Leukemia (CLL) [27] After chemoimmunotherapy”
BackgroundInfluentialProtein degradation technology: a strategic paradigm shift in drug discovery
Li, H., Dong, J., Cai, M., Xu, Z., Cheng, X.-D., & Qin, J.-J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01146-7 · Cited by 88
MYC Modulation around the CDK2/p27/SKP2 Axis
Hydbring, P., Castell, A., & Larsson, L.-G. (2017) · Genes · doi:10.3390/genes8070174 · Cited by 90
“Among the most important CDK2 substrates during G1-S progression are the RB-family of pocket proteins including the retinoblastoma protein (pRB) which is phosphorylated by cyclin E/CDK2 in cooperation with cyclin D/CDK4/6.”
BackgroundInfluentialEl‐Karim, S. S. A., Syam, Y. M., Kerdawy, A. M. E., & Abdelghany, T. M. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.01.026 · Cited by 100
“On the other hand, association with cyclin A, permits continuous DNA replication and properly programed deactivation of E2F [10].”
BackgroundTargeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
Weiß, A., Neubauer, M. C., Yerabolu, D., Kojonazarov, B. K., Schlueter, B. C., Neubert, L., Jonigk, D. D., Baal, N., Ruppert, C., Dorfmüller, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10135-x · Cited by 100
Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications
Sofi, S., Mehraj, U., Qayoom, H., Aisha, S., Asdaq, S. M. B., Almilaibary, A., & Mir, M. A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01731-x · Cited by 101
CDC7-independent G1/S transition revealed by targeted protein degradation
Suski, J. M., Ratnayeke, N., Braun, M., Zhang, T., Strmiska, V., Michowski, W., Can, G., Simoneau, A., Śnioch, K., Cup, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04698-x · Cited by 100
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
Yang, J., Chang, Y., Tien, J. C.-Y., Wang, Z., Zhou, Y., Zhang, P., Huang, W., Vo, J. N., Apel, I. J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00384 · Cited by 100
Al-Qasem, A. J., Alves, C. L., Ehmsen, S., Tuttolomondo, M., Terp, M. G., Johansen, L. E., Vever, H., Hoeg, L. V. A., Eliáš, D., Bak, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00311-6 · Cited by 103
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
Vijayaraghavan, S., Moulder, S., Keyomarsi, K., & Layman, R. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0541-2 · Cited by 99
“These results led to further preclinical and clinical studies using the CDK4/6i in ER positive breast cancer, which were highly successful [21].”
BackgroundMethodResultInfluentialPancholi, S., Ribas, R., Simigdala, N., Schuster, E. F., Nikitorowicz-Buniak, J., Ressa, A., Gao, Q., Leal, M. F., Bhamra, A., Thornhill, A. M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1284-6 · Cited by 98
Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms
Jia, Q., Chen, S., Tan, Y., Li, Y., & Tang, F. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0428-7 · Cited by 98
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors
Kalra, S., Joshi, G., Munshi, A., & Kumar, R. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.071 · Cited by 98
Kim, S., Tiedt, R., Loo, A., Horn, T., Delach, S., Kovats, S., Haas, K., Engstler, B. S., Cao, A., Pinzon-Ortiz, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26215 · Cited by 93
“Importantly, and consistent with the biochemical inhibition data, this selectivity extends to closely related family members such as CDK1 and CDK9 [21, 22], which are essential for the proliferation of normal cells [10] and should ideally be unaffected in order to avoid toxicities.”
Influential
Metadata
- Authors
- Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S.
- Affiliations
- Institute of Cancer Research (GB)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-30
- Volume
- 14
- Issue
- 2
- Pages
- 130-146
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4480421
- OpenAlex
- W2057272791
- Cited by
- 1,767
- References
- 210
- Citations by year
- 2026: 100 · 2025: 157 · 2024: 157 · 2023: 170 · 2022: 180 · 2021: 200 · 2020: 185 · 2019: 148 · 2018: 150 · 2017: 161 · 2016: 112 · 2015: 46
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Consortium canadien en neurodégénérescence associée au vieillissement
- Cancer Research UK (16642)
- National Cancer Institute (R01CA129134, CA129134, CA188650, R01CA188650, CA163863, R01CA163863)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinases, cyclin-dependent kinase inhibitors, CDK4, CDK6, CDK2, CDK1, cell cycle regulation, G1 phase, chromosome stability, S phase, anticancer drug development, clinical trials, patient stratification, kinase selectivity
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Molecular Structure, Signal Transduction, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.